200 related articles for article (PubMed ID: 16645163)
21. Lipid rafts as signaling hubs in cancer cell survival/death and invasion: implications in tumor progression and therapy: Thematic Review Series: Biology of Lipid Rafts.
Mollinedo F; Gajate C
J Lipid Res; 2020 May; 61(5):611-635. PubMed ID: 33715811
[TBL] [Abstract][Full Text] [Related]
22. Targeting Casein Kinase 1 (CK1) in Hematological Cancers.
Janovská P; Normant E; Miskin H; Bryja V
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261128
[TBL] [Abstract][Full Text] [Related]
23. Linking Immunoevasion and Metabolic Reprogramming in B-Cell-Derived Lymphomas.
Böttcher M; Baur R; Stoll A; Mackensen A; Mougiakakos D
Front Oncol; 2020; 10():594782. PubMed ID: 33251150
[TBL] [Abstract][Full Text] [Related]
24. AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma.
Bloedjes TA; de Wilde G; Maas C; Eldering E; Bende RJ; van Noesel CJM; Pals ST; Spaargaren M; Guikema JEJ
Blood Adv; 2020 Sep; 4(17):4151-4164. PubMed ID: 32898245
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of Skp2 Sensitizes Chronic Myeloid Leukemia Cells to Imatinib.
Chen X; Huang Z; Wu W; Xia R
Cancer Manag Res; 2020; 12():4777-4787. PubMed ID: 32606967
[TBL] [Abstract][Full Text] [Related]
26. Management of Drug Resistance in Mantle Cell Lymphoma.
Roué G; Sola B
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32545704
[TBL] [Abstract][Full Text] [Related]
27. Antitumor effects and mechanisms of 1,25(OH)2D3 in the Pfeiffer diffuse large B lymphoma cell line.
Han J; Tang Y; Zhong M; Wu W
Mol Med Rep; 2019 Dec; 20(6):5064-5074. PubMed ID: 31638226
[TBL] [Abstract][Full Text] [Related]
28. The Signal Transducer and Activator of Transcription 5B (STAT5B) Gene Promotes Proliferation and Drug Resistance of Human Mantle Cell Lymphoma Cells by Activating the Akt Signaling Pathway.
Zhang W; Liang X; Gong Y; Xiao C; Guo B; Yang T
Med Sci Monit; 2019 Apr; 25():2599-2608. PubMed ID: 30964854
[TBL] [Abstract][Full Text] [Related]
29. Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia.
Padgaonkar A; Rechkoblit O; Vasquez-Del Carpio R; Pallela V; Venkata Subbaiah D; Cosenza SC; Baker SJ; Ramana Reddy MV; Aggarwal A; Reddy EP
Oncotarget; 2018 Dec; 9(102):37753-37765. PubMed ID: 30701029
[TBL] [Abstract][Full Text] [Related]
30. Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies.
Ricci JE; Chiche J
Front Oncol; 2018; 8():556. PubMed ID: 30564554
[TBL] [Abstract][Full Text] [Related]
31. New quinoline/chalcone hybrids as anti-cancer agents: Design, synthesis, and evaluations of cytotoxicity and PI3K inhibitory activity.
Abbas SH; Abd El-Hafeez AA; Shoman ME; Montano MM; Hassan HA
Bioorg Chem; 2019 Feb; 82():360-377. PubMed ID: 30428415
[TBL] [Abstract][Full Text] [Related]
32. Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
Li CJ; Jiang C; Liu Y; Bell T; Ma W; Ye Y; Huang S; Guo H; Zhang H; Wang L; Wang J; Nomie K; Zhang L; Wang M
Mol Cancer Ther; 2019 Feb; 18(2):267-277. PubMed ID: 30413649
[TBL] [Abstract][Full Text] [Related]
33. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma.
Lee J; Zhang LL; Wu W; Guo H; Li Y; Sukhanova M; Venkataraman G; Huang S; Zhang H; Alikhan M; Lu P; Guo A; Galanina N; Andrade J; Wang ML; Wang YL
Blood Adv; 2018 Aug; 2(16):2039-2051. PubMed ID: 30115641
[TBL] [Abstract][Full Text] [Related]
34. Targeting the B cell receptor pathway in non-Hodgkin lymphoma.
Valla K; Flowers CR; Koff JL
Expert Opin Investig Drugs; 2018 Jun; 27(6):513-522. PubMed ID: 29855199
[TBL] [Abstract][Full Text] [Related]
35. Regulation of Hematopoietic Cell Development and Function Through Phosphoinositides.
Elich M; Sauer K
Front Immunol; 2018; 9():931. PubMed ID: 29780388
[TBL] [Abstract][Full Text] [Related]
36. Critically dysregulated signaling pathways and clinical utility of the pathway biomarkers in lymphoid malignancies.
Sun RF; Yu QQ; Young KH
Chronic Dis Transl Med; 2018 Mar; 4(1):29-44. PubMed ID: 29756121
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic Signaling Pathways and Pathway-Based Therapeutic Biomarkers in Lymphoid Malignancies.
Sun R; Wang J; Young KH
Crit Rev Oncog; 2017; 22(5-6):527-557. PubMed ID: 29604930
[TBL] [Abstract][Full Text] [Related]
38. The proto-oncogene Mer tyrosine kinase is a novel therapeutic target in mantle cell lymphoma.
Shi C; Li X; Wang X; Ding N; Ping L; Shi Y; Mi L; Lai Y; Song Y; Zhu J
J Hematol Oncol; 2018 Mar; 11(1):43. PubMed ID: 29554921
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.
Rudelius M; Rosenfeldt MT; Leich E; Rauert-Wunderlich H; Solimando AG; Beilhack A; Ott G; Rosenwald A
Haematologica; 2018 Jan; 103(1):116-125. PubMed ID: 29079592
[TBL] [Abstract][Full Text] [Related]
40. The role of B cell antigen receptors in mantle cell lymphoma.
Fichtner M; Dreyling M; Binder M; Trepel M
J Hematol Oncol; 2017 Oct; 10(1):164. PubMed ID: 29041946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
